ArticleBritish journal of haematology2011
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
Article in British journal of haematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.Haematologica · 2019Pooled it
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2026Article
- Myelofibrosis and allogeneic transplantation: critical points and challenges.Frontiers in oncology · 2024Review
- The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.Journal of personalized medicine · 2022Review
- Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.Leukemia · 2021Article
- Survival following allogeneic transplant in patients with myelofibrosis.Blood advances · 2020Article
- Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.Therapeutic advances in hematology · 2020Review
- Allogeneic Stem Cell Transplantation in Myelofibrosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Review
- [Advances in allogeneic hematopoietic stem cell transplantation for myelofibrosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Hematology/oncology clinics of North America · 2014Review
- Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Review
- Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Current opinion in hematology · 2014Review
- Hematopoietic Cell Transplantation for Older Patients with MDS.Mediterranean journal of hematology and infectious diseases · 2014Review
- Ruxolitinib for myelofibrosis.Experimental and therapeutic medicine · 2013Article
- The evolving treatment paradigm in myelofibrosis.Leukemia & lymphoma · 2013Review
- Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Blood reviews · 2012Review
- Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Blood · 2012Review
- Article
- Myelofibrosis 2012: it's complicated.Therapeutic advances in hematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We analysed the results of haematopoietic cell transplantation (HCT) in 30 patients aged 60-78 (median 65) years, with primary myelofibrosis or myelofibrosis evolving from antecedent polycythaemia vera or essential thrombocythaemia. Donors were human leucocyte antigen (HLA)-identical siblings (N = 15) or unrelated individuals (N = 15). Various conditioning regimens were used, ranging from very low intensity (fludarabine plus 2 Gy total body irradiation) to high dose (busulfan plus cyclophosphamide). Stem cell sources were granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells in 29 patients and marrow in one patient. Sustained engraftment was documented in 27 of 30 patients. Day -100 mortality was 13%. With a median follow-up of 22 (range 0·5 - 69) months, 3-year overall survival and progression-free survival were 45% and 40%, respectively. Currently, 13 patients are surviving. Seven patients died with disease progression at 0·5 -22 months, and 10 patients died from other causes at 1·5 -37.5 months after HCT. While the selection of older patients for transplantation was probably biased, the present results are encouraging. Motivated older patients with myelofibrosis without substantial comorbid conditions should be offered the option of allogeneic HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.